Aspect Partners’s Protara Therapeutics TARA Stock Holding History

Aspect Partners’s Portfolio TARA Stock Details TARA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$769	Buy	252 +22	+10%	+$86	﹤0.01%	611
2026 Q2	$879	Buy	230 +124	+117%	+$590	﹤0.01%	589
2026 Q1	$552	Buy	+106	New	+$627	﹤0.01%	651

Other funds holding TARA

Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return

Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

Aspect Partners's TARA Position: Q3 2026 in Review

Aspect Partners increased its Protara Therapeutics (TARA) stake by 9.6% in Q3 2026, buying an estimated $86 and bringing the position to 252 shares worth $769. The position accounts for ﹤0.01% of the portfolio, ranked #611.

Aspect Partners first reported a position in TARA in Q1 2026 and has held it in 3 quarters since. The position peaked at $879 in Q2 2026. 6 funds tracked by Wall St. Rank hold TARA as of Q3 2026.

Aspect Partners held 252 shares of Protara Therapeutics worth $769 as of Q3 2026.
Aspect Partners bought 22 Protara Therapeutics shares in Q3 2026, an estimated $86.
Protara Therapeutics made up ﹤0.01% of Aspect Partners's portfolio in Q3 2026, its #611 holding.
Aspect Partners first reported a position in Protara Therapeutics in Q1 2026 and has held it in 3 quarters since.
Aspect Partners's Protara Therapeutics position peaked at $879 in Q2 2026.
6 funds tracked by Wall St. Rank held Protara Therapeutics as of Q3 2026.

Based on Aspect Partners's 13F filing for Q3 2026, filed 20 Oct 2026.